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Abstract 
ARNT isoforms differentially regulate cancer cell growth through a 
p53-dependent mechanism. 
Krishnakali Sarkar, MA 
The University of Texas at Austin, 2014 
Supervisor:  Casey W. Wright 
Aryl hydrocarbon receptor nuclear translocator (ARNT) is an important player in 
xenobiotic and hypoxic responses. In addition to this, my mentor has shown that ARNT 
is an integral cofactor of NF-𝛋B signaling. However, these initial observations of ARNT-
mediated NF-𝛋B modulation were based on simultaneous suppression of the two ARNT 
isoforms, isoform 1 and 3, and therefore precluded the isolated examination of each 
isoform’s function. We show here that lymphoid malignancies exhibit higher levels of 
ARNT isoform 1 compared to ARNT isoform 3. However, normal T and B lymphocytes 
are seen to harbor equal levels of ARNT isoform 1 and 3.  We hypothesize that the 
increase in ARNT isoform 1 is necessary for the growth of these cancer cells as 
suppression of isoform 1 resulted in S-phase cell cycle arrest. These findings reveal that 
ARNT isoform 1 potentiates cell growth by antagonizing a p53 cell cycle inhibitory 
vii 
mechanism and this further suggests that ARNT targeted therapies would benefit 
chemotherapy regimens. 
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Chapter 1:  Introduction 
1.1 Background 
The aryl hydrocarbon receptor nuclear translocator (ARNT, also known as 
hypoxia inducible factor-1β) is a ligand-dependent transcription factor. ARNT along with 
its partner, aryl hydrocarbon receptor (AHR), together referred to as the aryl hydrocarbon 
receptor complex (AHRC), binds to structurally diverse synthetic and naturally occurring 
chemicals including dioxins, flavonoids and tryptophan photoproducts (Denison and 
Nagy, 2003). The environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is 
the most potent known cytochrome P4501A1 inducer and ARNT, along with its binding 
partner AHR, have been long associated with an organism’s response to various 
environmental contaminants like TCDD (Whitlock, 1999). ARNT is a class II bHLH-
PAS transcription factor and the general heterodimerization partner for many bHLH 
proteins including AHR, hypoxia-inducible factor 1 and 2 (HIF-1α and 2α), and single-
minded protein 1 and 2 (SIM1 and 2) (McIntosh et al., 2010). AHR-ARNT heterodimers 
regulate genes involved in the metabolism of xenobiotics (Hankinson, 1994), whereas 
ARNT-HIF-1α heterodimers regulate genes involved in the response to oxygen 
deprivation (Bunn and Poyton, 1996). 
1.2 Structure of ARNT 
ARNT is a member of the basic helix-loop-helix Per/AHR/ARNT/Sim (bHLH-
PAS) family of transcription factors. The amino (N) terminal end of ARNT contains the 
bHLH-PAS domain, and the ligand-binding domains (Fukunaga et al., 1995). This 
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portion also includes the nuclear localization signal (NLS) and appears to have two 
nuclear export signals (NES) (Ikuta et al., 1998). The HLH domain is responsible for 
dimerization with a homologous or heterologous partner. The adjacent basic region 
mediates sequence specific binding. The structural analysis of the cloned cDNA revealed 
that the ARNT sequence contains a conserved region called PAS domain shared by 
Drosophila Per, Ah receptor (AHR), and Drosophila Sim (Hoffman et al., 1991). The 
PAS domain has about 260 amino acids containing two short stretches of internal direct 
repeats called PAS A and PAS B (Nambu et al., 1991). The PAS domains of Per and Sim 
mediate heterodimerization between these proteins, whereas the PAS domain of Per can 
also mediate homodimerization (Huang et al., 2013). The carboxy (C) terminal end of 
ARNT contains a transactivation domain (TAD), which has three subdomains, the acidic, 
glutamine-rich, and proline-serine-threonine rich domains (Ma et al., 1995). The TA 
domain is the key determinant of cellular localization and ligand-independent 
nucleocytoplasmic shuttling properties (Ramadoss and Perdew, 2005). Once the mouse 
ARNT (Reisz-Porszasz et al., 1994) and human AHR (Itoh and T, 1993) were cloned, it 
was evident that the ARNT and AHR of both the species were about 20% identical to 
each other in their amino acid sequence and had a striking resemblance in their overall 
structure (Hankinson, 1994). The ARNT gene is found to be located on human 
Chromosome 1q21 and on mouse Chromosome 3 near Cf-3 (Doedens et al., 2013) 
whereas AHR is located on human chromosome 7 (Le Beau et al., 1994) and mouse 
chromosome 12 (Poland et al., 1987). 
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ARNT is expressed as two alternatively spliced isoforms, ARNT isoform 1 and 
ARNT isoform 3 in humans, or Arnt-a and Arnt-b in mice. ARNT Isoform 1 has 789 
amino acids and isoform 3 has 774 amino acids, thus differing in 15 amino acids found 
near the N-terminus of isoform 1 (Hoffman et al., 1991) (Figure 1.1). These unique 15 
amino acids in isoform 1 are mainly due to the inclusion of exon 5 by the splice 
machinery. Interestingly, the amino acids encoded by exon 5 are directly upstream of the 
bHLH DNA binding motif and the last 2 carboxyl amino acids contribute to DNA 
interactions (Sun et al., 1997). In ARNT isoform 3 where exon 5 is missing, the junctions 
come together to reiterate the start of the bHLH DNA binding motif. This provides an 
extra phosphorylation site on exon 5, a serine 77, which has been shown to have a 
profound affect on ARNT isoform 1 DNA binding activity. Initial work from our 
laboratory has shown that equal amounts of ARNT isoforms are present in a number of 
human cell types like the T and the B lymphocytes, hepatocytes and epithelial cells 
(unpublished data). Based on our initial data we hypothesize that the expression of ARNT 
isoforms is different in malignant cell lines and different ARNT isoforms differentially 
regulate cancer growth. 
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Figure 1.1: Schematic representation of ARNT isoform 1 and 3. 
The N terminal has the bHLH-PAS domain, the C terminal end has the TA domain. 
ARNT Isoform 1 has 789 amino acids and isoform 3 has 774 amino acids, thus differing 
in 15 amino acids found near the N- terminus of isoform 1. 
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1.3 The AHR/ARNT Signaling Pathway 
Many endogenous and exogenous chemicals possess the ability to bind to and 
activate AHR. Endogenous compounds that are thought to activate the AHR are bilirubin 
or various tryptophan metabolites. However, the majority of the known AHR activating 
compounds are synthetic in nature. Classical chemical compounds that activate the AHR 
include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), benzo(a)pyrene (B(a)P), 3-
methylcholanthrene (3MC), β-naphtoflavone and the dioxin-like polychlorinated 
biphenyls (PCB) which have a coplanar conformation that allows binding to the AHR (Denison	   and	   Nagy,	   2003) . AHR target genes include phase I detoxifying enzymes 
such as the cytochrome P450 (CYP) 1 family members as well as phase II detoxifying 
enzymes such as aldehyde dehydrogenase 3, UDP-glucuronosyl transferase, and 
glutathione S-transferase (Beischlag et al., 2008). 
In its nonligand state, the AHR resides in the cytoplasm in an inactive form bound 
to a chaperone protein complex that includes heat shock protein 90	   (McGuire et al., 
1994b), AHR-interacting protein (AIP), and p23 (Hankinson, 1994)	   (Nair et al., 1996). 
Once activated by a ligand, AHR translocates into the nucleus where it is released from 
the complex and then it associates with its heterodimerization partner ARNT	  (McGuire et 
al., 1994a). The AHR/ARNT heterodimer then binds to its cognate DNA sequence motif, 
referred to as the dioxin-responsive element (DRE), or AHR-responsive element (AHRE; 
5′-TNGCGTG-3′) with a minimum core sequence of 5′-GCGTG-3′ upstream of a 
responsive gene such as cytochrome P450 1A1 (CYP1A1) and other AHR-dependent–
responsive genes. This leads to DNA bending, recruitment of coactivators, chromatin and 
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nucleosome disruption, increased promoter accessibility to transcription factors, and 
increased rates of gene transcription (Beischlag et al., 2008), (Swanson, 2002). 
Once bound to chromatin, the activated AHR/ARNT heterodimer induces the 
recruitment of coregulator proteins resulting in changes in the target gene expression, 
including CYP1A1, CYP1B1, nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; 
NRF2), and AHRR (Whitlock, 1999), (Zhang et al., 2013). AHR/ARNT heterodimers 
also recruits components of the SWI/SNF complex that remodel chromatin, coactivators 
such as the steroid receptor coactivator-1 (SRC-1) with histone acetyltransferase (HAT) 
activity, and components of the positive transcription elongation factor (P-TEFb) (Tian et 
al., 2003) to control activity or the general transcription machinery (GTM). 
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Figure 1.2: The AHR/ARNT signaling pathway. 
Adapted from Brigitta Stockinger Annu. Rev. Immunol. 2014. 
In the absence of a ligand, AHR is present in the cytoplasm bound as an inactive complex 
with several chaperone proteins, including HSP90, AIP, and p23. Upon ligand binding, it 
translocates into the nucleus, where it is released from the complex, heterodimerizes with 
its protein partner ARNT, and finally binds genomic regions containing its binding motif 
[dioxin response element (DRE)], inducing transcription of target genes such as 
CYP1A1, CYP1A2, CYP1B1, and AHR represor (AHRR). AHR signaling is regulated at 
three levels: proteasomal degradation of AHR, ligand metabolism by CYP1A1, and 
AHR/ARNT complex disruption by AHRR. 
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Figure 1.3: AHR/ARNT heterodimers recruits components of the SWI/SNF complex. 
Adapted from Brigitta Stockinger Annu. Rev. Immunol. 2014. 
AHR/ARNT heterodimers recruit multiple protein partners to regulate transcriptional 
activation of their target genes. These include components of the SWI/SNF complex that 
remodel chromatin, coactivators such as the steroid receptor coactivator-1 (SRC-1) with 
histone acetyltransferase (HAT) activity, and components of the positive transcription 
elongation factor (P-TEFb) to control activity or the general transcription machinery 
(GTM). 
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1.4 Regulatory involvement of ARNT in NF-κB signaling 
The pleiotropic transcription factor, nuclear factor-κB (NF-κB), is essential in the 
regulation of innate and adaptive immunity (Staudt, 2010). NF-κB controls inflammation 
by regulation of gene transcription, which is achieved through differential dimerization of 
five subunits: Rel-A, Rel-B, c-Rel, p105/p50, and p100/p5 (Ghosh and Hayden, 2012). 
The subunits homodimerize or heterodimerize through a common rel homology domain 
(RHD) to form transcriptionally active dimers.  Prior to receiving a signal, NF-κB dimers 
are kept inactive in the cytoplasm by binding the inhibitors of NF-κB (IκB). Once the 
NF-κB pathway is initiated, a signaling cascade causes the ubiquitination and 
proteasomal degradation of the IkB proteins, allowing the dimers to translocate to the 
nucleus to regulate gene transcription. There are two NF-κB pathways that are defined by 
the dimer that gets released: canonical and noncanonical (alternative) pathways.  The 
canonical pathway is characterized by degradation of IκBα followed by the release of 
RelA-p50 dimers; while, in noncanonical signaling, processing of p100 to p52 releases 
RelB-p52 dimers (Hayden and Ghosh, 2012), (Sun, 2012). NF-κB requires a number of 
negative regulatory mechanisms to prevent excess transcriptional activity that can lead to 
chronic inflammation, autoimmune diseases, and cancer (Ruland, 2011). One example is 
the subunit RelB.  RelB was originally identified as an inhibitor of the subunit p50.  RelB 
negatively regulates the canonical NF-κB pathway, most likely through its association 
with p50 (Ruben et al., 1992). My mentor in his previous studies discovered that ARNT 
binds to RelB and has a negative regulatory effect on NF-κB signaling. RelB is present at 
classical RelA-p50 regulated target promoters. Upon initial signaling, RelA-p50 
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translocates to the nucleus where it replaces the RelB complex. Once stimulated, RelB 
translocates to the nucleus where it associates with ARNT thus enhancing the binding of 
RelB to DNA and negatively regulating RelA-p50complexes (Wright et al., 2007). 
However, AHR and ARNT are also found to differentially and independently regulate 
NF-κB signaling and chemokine CXCL8 (IL8), CCL5 (RANTES) responses induced by 
both inhaled pollutants and pulmonary infection. Overik J et al. propose that AHR 
signaling may be a weak activator of p65 signaling that suppresses p65 activity induced 
by strong activators of NF-κB (Ovrevik et al., 2014). 
Adapted from Wright C.W. Science (2009) 	  
Figure 1.4: Proposed model of ARNT regulation of NF-κB activity.  
Aryl hydrocarbon receptor nuclear translocator (ARNT) binds to RelB to promote higher affinity 
of RelB DNA binding. Consecutively, RelB has a negative regulatory effect on canonical NF-κB 
signaling. Before stimulation RelB is present at classical RelA-p50 regulated target promoters.  
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1.5 The role of AHR in NF-κB signaling 
The AHR is a cytoplasmic receptor for xenobiotic ligands. For decades AHR has 
been recognized as the key mediator of xenobiotic responses to environmental pollutants. 
These pollutants include polycyclic aromatic hydrocarbons like [B(A)P] and halogenated 
hydrocarbons such as TCDD, one of the most potent activators of AHR (Denison	  and	  Nagy,	   2003). The AHR and NF-κB are both inducible transcription factors, each 
governing the expression of distinct sets of genes that are important for the normal 
physiology as well as for pathophysiological responses. Recent reports suggest that AHR 
affects the expression and function of many immunoregulatory genes and also has an 
influence on differentiation of inflammatory dendritic cells (Bankoti et al., 2010). 
Furthermore, AHR also plays a critical role in T-cell differentiation and immunity of the 
gut (Quintana et al., 2008), (Veldhoen et al., 2008). Denison et al. in their recent study 
has dissected the molecular mechanisms of AHR activity in immune cells during 
inflammation (Vogel et al., 2014b). NF-κB is a key transcription factor in regulating the 
immune system and inflammatory responses. AHR has gradually emerged as a regulator 
of inflammation in various tissues. There seems to be a crosstalk between the AHR and 
NF-κB family of transcription factors (Tian et al., 2002), (Vogel et al., 2014a). In their 
present study, Denison et al. gave an insight into the mechanism of the regulation of the 
human AHR gene through NF-κB signaling. Elevated expressions of AHR-regulated 
genes were documented upon LPS stimulation. LPS activated NF-κB signaling, in a 
RelA-dependent manner, which in turn increased the expression of AHR and CYP1A1 
	   12	  
(Vogel et al., 2014a). This signifies that inflammatory stimuli and cytokines that regulate 
NF-κB induce AHR expression during activation and differentiation of immune cells. 
 
1.6 p53 “The guardian of the genome” 
 p53 is an intensively studied protein, its importance is mainly due to the role it 
plays as a tumor suppressor in humans and other mammals. The p53 gene is the most 
frequently mutated gene in human cancers, about 50% of all human cancers have a 
mutated p53 or an inactive version of p53 (Toledo and Wahl, 2006). In brief, p53 is a 
master transcription factor that under normal conditions is usually functionally inactive 
due to its rapid degradation by the ubiquitin ligase MDM2. However, upon the infliction 
of almost literally any cellular stress, MDM2-driven degradation is jeopardized, and p53 
accumulates and gains full control in transcriptional activation (Hayon and Haupt, 2002). 
The p53 transcriptional cascade includes the activation of a number of cell cycle 
inhibitors and pro-apoptotic proteins, which results in apoptosis or irreversible 
proliferative arrest, also known as senescence (Vousden and Lu, 2002). Two types of 
stresses that are targeted to p53 are DNA damage and oncogenic signaling. DNA damage 
was the first type of stress found to activate p53 and based on this, p53 has been widely 
and rightly regarded as “the guardian of the genome” (Chao et al., 2000). The other factor 
that is found to activate p53 is oncogenic signaling. Therefore, analogous to the title 
“guardian of the genome”, p53 is also assigned the function of “policeman of the 
oncogenes”(Efeyan and Serrano, 2007). Briefly, oncogenic signaling activates p53 
through ARF (Palmero et al., 1998),
 
which interacts with MDM2 inhibiting its p53-
	   13	  
ubiquitin ligase activity. In this manner, ARF-dependent stabilization of p53 results in a 
dramatic increase in p53 activity. Further experiments by Efeyan et al demonstrated that 
DNA damage response of p53 is of minor importance for cancer protection and this 
tumor protective activity of p53 was mainly dependent on the presence of ARF, as the 
oncogenic signaling mediated activation of p53 was completely lost in the absence of 
ARF in ARF-null mice (Efeyan and Serrano, 2007). Thus, it is well documented that 
activation of p53 occurs in response to a number of cellular stresses, including DNA 
damage which eventually leads to the activation of several genes whose products trigger 
cell cycle arrest, apoptosis, or DNA repair (Lakin and Jackson, 1999), (Laptenko and 
Prives, 2006).  
 Experiments in our laboratory with the suppression of ARNT isoform 1 using 
siRNA, resulted in cell cycle arrest. Since, p53 is the key regulator of cell cycle arrest, 
this guided us to postulate that p53 was involved in this process. We further wanted to 
explore whether changes in ARNT expression would have any effect on p53 activation in 
malignant lymphoid cells. 
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Chapter 2: Experimental Design and Methods 
2.1 Cell culture and Reagents: 
Karpas 299 cells were cultured in RPMI-1640 medium (Cellgro) supplemented with 10% 
fetal bovine serum (Atlas Biologicals, Inc.) and 2 mM Glutamax (Life Technologies) at 
37 °C and 5% CO2. For transfections, cells were recovered in RPMI-1640 supplemented 
with 20% fetal bovine serum and 2 mM Glutamax. Human T and B lymphocytes were 
isolated using the MACS Miltenyi Biotec CD4 T Cell Isolation Kit. Unless otherwise 
stated, all reagents and chemicals were obtained from Sigma- Aldrich (St. Louis, MO) 
2.2 RNA interference 
Cells were transfected by electroporation as described (Wright 2007). Briefly, 10 × 10
6
cells (at 25 × 10
6 
cells/mL) were electroporated using a Gene Pulsar Xcell (Bio-Rad)
with 2 µM control, ARNT isoform 1 or ARNT isoform 1 and 3 target siRNA duplexes. 
Immediately after electroporation, cells were placed in recovery media (20% serum) for 
16 hours and then transferred to growth media (10% serum) at 0.5 x 10
6
/ mL for an 
additional 24 hours. Control, ARNT isoform 1and ARNT isoform 3 siRNA duplexes 
were obtained from Sigma-Aldrich.  
Target sequences are listed in Table 2.1:  
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Control- sense 5’-CAUGCCUUGCUUUACGCAUTT-3’ 
Control- antisense 5’-AUGCGUAAAGCAAGGCAUGTT-3’ 
ARNT isoform1- sense 5’-UGCCAGGUCGGAUGAUGAGCA-3’ 
ARNT isoform1- antisense 5’- UGCUCAUCAUCCGACCUGGCA-3’ 
ARNT isoform1/3 sense 5’-UCCAGUCUCAGGAGCAAAG-3’ 
ARNT isoform1/3 antisense 5’-AAACUGGGAAGUACGAGUC-3’ 
Table 2.1: siRNA target sequences. 
2.3 Antibodies and Immunoblotting 
After electroporation the cells were harvested. Lysates from cells were prepared by 
incubating cells on ice in radioimmune precipitation (RIPA) buffer (PBS containing 1% 
Nonidet P-40, 0.5% (w/v) deoxycholic acid, 0.1% SDS, 1 mM PMSF, and 1 mM DTT) 
supplemented with complete mini protease inhibitor tablets (Roche Diagnostics). The 
cells were then incubated on ice for 20 minutes and centrifuged at 4 °C at 21,000 x g for 
10 minutes. Protein lysates were then resolved on denaturing polyacrylamide gels, 
transferred to nitrocellulose (Whatman) membrane, and blocked with 5% powdered milk 
(w/v) in Tris-buffered saline with Tween 20. (TBS-T; 20mM Tris-HCL, pH 7.6, 137mM 
NaCl containing 0.1% Tween 20). The membranes were incubated with the following 
primary antibodies, washed, and then incubated with horseradish peroxidase-conjugated 
secondary antibodies (GE Healthcare). Peroxidase activity was then detected by the 
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enhanced chemiluminescence Western blot analysis system (GE Healthcare). Antibodies 
used are: β-Actin (Sigma-Aldrich), ARNT (BD Biosciences), IκB-α (Millipore), p53 
(Invitrogen), phosphorylated p53S15(R & D systems). 
 
2.4 Cell cycle analysis 
After 48 hours of siRNA treatment cells were harvested and washed with PBS. Cells 
were fixed at a concentration of 1 × 10
6 
in 1 mL of 50% ethanol in PBS for 1 hour at -20 
°C. The ethanol was then removed from the cells and then placed in PBS containing 50 
µg/mL of propidium iodide and 100 µg/mL of RNAse A. Flow cytometry was performed 
using the Beckman Coulter Cytomics FC500 and data analysis was performed using 
FlowJo (Tree Star Inc.). 
 
2.5 Isolation of T and B-lymphocytes 
Freshly drawn normal leukocytes were obtained from The New York Blood Center with 
proper IRB certification. Human peripheral blood mononuclear cells (PBMC) from the 
leukocytes were isolated by Ficoll centrifugation at 500 x g for 30 minutes. The cells in 
the buffy layer are washed with PBS and cultured overnight in RPMI 1640 media. Using 
the MACS Miltenyi Biotec CD4 T Cell Isolation Kit, human T lymphocytes cells are 
isolated by depletion of non-target cells (negative selection). Non-target cells are labeled 
with a cocktail of biotin-conjugated monoclonal antibodies and the CD4 T Cell Micro 
Bead Cocktail. The magnetically labeled non-target T cells are depleted by retaining 
them on a MACS® Column in the magnetic field of a MACS Separator, while the 
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unlabeled T helper cells pass through the column. Similarly, using the MACS Miltenyi 
Biotec B Cell Isolation Kit II, human B cells are isolated by depletion of non-B cells 
(negative selection). Non-B cells are indirectly magnetically labeled with a cocktail of 
biotin-conjugated monoclonal antibodies, as primary labeling reagent, and anti-biotin 
monoclonal antibodies conjugated to Micro Beads, as secondary labeling reagent. The 
magnetically labeled non-B cells are depleted by retaining them on a MACS® Column in 
the magnetic field of a MACS Separator, while the unlabeled B cells pass through the 
column.  
 
2.6 Statistics 
Statistical significance was evaluation by using the student’s t-test. A P value of p<0.05 
was considered statistically significant. 	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Chapter 3: Results and Discussion 
3.1 ARNT levels in normal T cells, B cells and Karpas 299 cells 
 To study the ARNT levels in lymphoid malignancies, lysates from the T cell 
derived anaplastic large cell lymphoma (ALCL) cell line, Karpas 299, were subjected to 
western blot analysis with ARNT antibody. In addition we examined ARNT isoform 
expression in human T and B lymphocytes. Immunoblot analysis of the lysates showed 
high levels of ARNT isoform 1 as compared to ARNT isoform 3 in Karpas 299 cells 
(Figure 3.1). This result is consistent with previous results from our laboratory showing 
an increase in ARNT isoform 1 levels in various other lymphoid malignancies. Our 
laboratory for the first time has shown that this increase in ARNT isoform 1 levels is 
mainly necessary for the growth of ALCL and multiple myeloma (MM) cancer cell lines. 
However, naive human T and B lymphocytes expressed equal amounts of both isoforms 
with T cells displaying higher ARNT expression than B cells.  
 
3.2 ARNT isoforms differentially regulates p53 activity 
 Data from our laboratory have demonstrated that suppression of ARNT isoform 1 
leads to changes in the expression of cell cycle genes like p21 and p15. It is well known 
that p53 is one of the key regulators of cell cycle arrest. Here, we sought to extend these 
findings by determining whether changes in the expression of ARNT isoforms will 
impact p53 activity, a key regulator of cell cycle arrest. To dissect the involvement of 
ARNT in regulating p53 activity, we used ARNT isoform specific siRNA to suppress 
isoform 1 (siARNT-1) or siRNA that targeted both isoforms  (siARNT-1/3). Karpas 299 
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cells were transfected with the indicated siRNA duplexes for 48 hours followed by 
western blot analysis to determine phospho and total p53 levels as well as ARNT isoform 
1 and 3 levels. The siRNA used in this experiment were effective in reducing ARNT 
isoform 1 and 3 protein levels as shown in Figure 3.2 panel C. Interestingly, our results 
indicate that supression of ARNT isoform 1 leads to an increased phosphorylation of p53 
indicative of p53 activation. Conversely, suppression of both ARNT isoforms 1 and 3 
leads to decreased phosphorylation of p53 (Figure 3.2 Panel A), most likely linked to the 
fact that we observed a concomitant decrease in total p53 levels upon suppression of both 
ARNT isoforms 1 and 3. The stabilization and activation of p53 in our system was 
measured by the phosphorylation of serine 15 of p53. (Figure 3.2 Panel B). Panel D 
shows the confirmation of the ARNT isoform specific RNAi. 
 
3.3 Cell cycle profile of Karpas 299 cells transfected with the indicated siRNA 
duplexes. 
 Based on our results, we hypothesized that transfection of Karpas 299 cells with 
siRNA targeting ARNT isoform 1 will lead to cell cycle arrest due to increased activation 
of p53, whereas transfection of siRNAs targeting both ARNT isoforms will not affect cell 
cycle progression. To study the cell cycle profile, Karpas 299 cells were transfected with 
the indicated siRNA duplex (Figure 3.3). Our results indicate that suppression of ARNT 
isoform 1 reduces cell growth in this malignant lymphoid cell line due to a S-phase cell 
cycle arrest. Flow cytometric analysis indicated that the number of cells arrested in the S 
phase was higher in cells transfected with siRNA against ARNT isoform 1 in comparison 
to those transfected with control siRNA or siRNA targeting ARNT isoform 1 and 3. 
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These results provide functional evidence for increased p53 activation by the suppression 
of only ARNT isoform 1 in Karpas 299 cells, thus suggesting that ARNT isoform 3 is 
mediating p53 activation. Further, preliminary data from our laboratory has shown that 
this cell cycle arrest correlates with increased expression of cell cycle inhibitory genes 
like p15 and p21. 
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Figure 3.1: ARNT levels in normal T cells, B cells and Karpas 299 cells. 
The ARNT isoform ratio is equal in normal lymphocytes. T cells express more ARNT as 
compared to B cells. T and B cells were isolated from healthy human donors, lysed and 
analyzed by Western blotting with anti ARNT. For comparison the T cell derived ALCL 
cell line Karpas 299 were run alongside T and B cells.  
 
iso 1	  
iso 3	  ARNT	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Figure 3.2:  ARNT isoforms differentially regulates p53 activity. 
Cells were transfected with control scrambled siRNA or si RNA directed against ARNT 
isoform 1 and 3. Equal amount of proteins were loaded, protein levels of p53, p53S15 and 
ARNT were detected by western blotting as described in experimental design and 
methods. 
Panel A: Stabilization and activation of p53 as measured by phosphorylation of serine 15 
Panel B: p53 is stabilized and activated in the nucleus with suppressed ARNT-1 
Panel C: Confirmation of the ARNT isoform specific RNAi. 
Panel D: Actin was used as a control for protein loading. 
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Figure 3.3: Flow cytometry was conducted to assess the cell cycle profile. 
ALCL (Karpas 299) cells were transfected with either siRNA control (C) or ARNT 
isoform 1 or 3 for 48 hours and then stained with propidium iodide (PI) to examine the 
cell cycle profile by flow cytometry.  
Suppression of ARNT isoform 1 reduces cell growth in this malignant lymphoid cell line 
due to a S-phase cell cycle arrest. 
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3.4 Discussion: 
 Genetic mutations including deletions, chromosomal translocations, transitions 
and amplifications are a common phenomenon in lymphoid malignancies. Cancer cells 
often produce multiple gene copies of proteins that promote proliferation and survival. 
Many of the isoforms produced in this manner are developmentally regulated and are 
preferentially re-expressed in tumors (David CJ). Earlier data from our laboratory has 
shown that ARNT is expressed as two alternatively spliced isoforms in most, but not all, 
cell types including hepatocytes, epithelial cells, fibroblasts and lymphocytes. 
Interestingly, ARNT is found to be the most highly amplified gene observed in certain T 
cell lymphoma, MM tumors and malignant plasma B cell lines established from MM 
patients (Bergsagel L, personal communications). Work from our laboratory has also 
demonstrated an increase in ARNT isoform 1 in various lymphoid malignancies. Earlier 
data from our laboratory clearly showed high levels of ARNT isoform 1 as compared to 
ARNT isoform 3 in Karpas 299 cells. Expression of multiple gene copies of ARNT may 
be responsible for disrupting the alternative splicing machinery (Faustino NA), as a result 
of which there is an increased presence of ARNT isoform 1. Thus, we have now shown 
that increased ARNT isoform 1 promotes the growth of lymphoid malignancies.  
 Our data shows that suppression of ARNT isoform 1 results in increased 
expression of p15 and p21, genes that are involved in cell cycle arrest. Since p53 is the 
key regulator of cell cycle arrest, we wanted to determine whether decreases in ARNT 
isoform 1 protein would affect p53 stability and/or activity in Karpas 299 cells. Indeed, 
our data demonstrates for the first time that p53 is stabilized and activated in Karpas 299 
	   25	  
cells after suppression of ARNT isoform 1. However, in contrast to our findings where 
ARNT isoform 1 was suppressed, simultaneous suppression of both ARNT isoforms 1 
and 3 leads to a decrease in phosphorylated p53. More importantly, this leads to an 
overall reduction in p53 protein levels. One possible interpretation of this result is that 
ARNT isoform 1 functions to suppress ARNT isoform 3. Hence, suppression of ARNT 
isoform 1 relieves ARNT isoform 3, and leads to enhance p53 activation. Our data 
reveals a very stable p53 after suppression of ARNT isoform 1 but not so after 
suppressing both the ARNT isoforms.  
 Analysis of the cell cycle profile of Karpas 299 cells transfected with the ARNT 
siRNA duplexes revealed that suppression of ARNT isoform 1 resulted in a S-phase cell 
cycle arrest. Thus we can conclude that an increase in ARNT isoform 1 in Karpas 299 
cells is necessary for the growth of ALCL cancer cells since the suppression of ARNT 
isoform 1 resulted in S-phase cell cycle arrest. Based on this data along with other data 
from our laboratory we propose a working model to explain the effects of ARNT on cell 
cycle progression (Figure 3.4). According to our model, ARNT isoform 1 is inhibitory 
and so suppressing ARNT isoform 1 releases ARNT isoform 3 and RelB. There are three 
possible mechanism of action, ARNT isoform 3 and RelB can directly regulate cell cycle 
genes or can regulate p53, which in turn regulates cell cycle genes. It may also regulate 
cytokine macrophage inhibitory cytokine 1 (MIC 1) that feedback in an autocrine manner 
to activate p53 and induce cell cycle arrest. So, ARNT has some effect directly or 
indirectly on the cytokine expression through modulating p53 and cell cycle genes. 
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 Our future goal is to define the mechanism of ARNT assisted cancer cell growth. 
Importantly, the fact that an increase in ARNT isoform 1 levels, in lymphoid 
malignancies, gives a growth advantage suggesting that ARNT isoform 1 would be a 
good target for therapeutic intervention. Therefore, our long-term goal is to elucidate the 
role of ARNT in regulating key immune signaling pathways, which will be the stepping-
stone to the development of not only anticancer therapies but also therapies against 
various other autoimmune diseases. 
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Figure 3.4: Working hypothetical model 
 
ARNT isoform 1 is inhibitory and so suppressing ARNT isoform 1 releases ARNT 
isoform 3 and RelB. There are three possible mechanism of action, ARNT isoform 3 and 
RelB can directly regulate cell cycle genes or can regulate p53, which in turn regulates 
cell cycle genes. It may also regulate cytokine macrophage inhibitory cytokine 1 (MIC 1) 
that feedback in an autocrine manner to activate p53 and induce cell cycle arrest. So, 
ARNT has some effect directly or indirectly on the cytokine expression through 
modulating p53 and cell cycle genes. 
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Chapter 4: Regulation of alcohol consumption by inflammation. 
 One of my other projects was concerned with the influence of NF-κB in the brain. 
More importantly, we wanted to analyze the effect of neuro-inflammation on inducing 
alcohol consumption. As such unmitigated inflammation is an important contributor to 
disease in a variety of tissues, and interestingly, has been implicated as a contributing 
factor to alcoholism. However, it is unclear exactly which cell types namely microglia or 
astrocytes contribute to the neuro-inflammation that facilitates alcohol consumption. We 
were mainly interested in looking at the effects of alcohol on brain microglia. 
 
4.1 Introduction: 
 Microglia are the resident macrophage like cells in the brain that paly a major role 
in the host defense and tissue repair in the central nervous system (CNS)	   (Kreutzbe, 
1996). Under pathological conditions, activated microglia release neurotoxic and pro-
inflammatory mediators, including nitric oxide (NO), prostaglandin E2 (PGE2), reactive 
oxygen species and pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6 and 
tumor necrosis factor (TNF)-α (Meda et al., 1995), (Dandona et al., 2010). 
Overproduction of these inflammatory mediators and cytokines causes severe 
neurodegenerative diseases, including Alzheimer’s disease (Perlmutter et al., 1990), 
Parkinson’s disease, cerebral ischemia, multiple sclerosis (Banati and Graeber, 1994) and 
trauma (Dheen et al., 2007). Activated microglia are a major source of pro-inflammatory 
and/or cytotoxic factors that cause neuronal damage in the CNS (Eikelenboom and van 
Gool, 2004). Previous studies have also demonstrated that a decrease in the number of 
pro-inflammatory mediators in microglia may attenuate the severity of these disorders 
	   29	  
(Gao et al., 2003) and (Liu and Hong, 2003). Hence, microglia cells are extensively 
studied to access brain inflammation. However, for a typical preparation of rodent 
microglia a number of brains are required to yield cells for a limited amount of 
experiments on signaling and disease mechanism. To overcome this limitation most of 
the microglial activation and signaling are performed in vitro, using BV2 cells. BV2 cells 
were derived from raf/myc immortalized murine neonatal microglia (Blasi et al., 1990) 
and are the most frequently used substitute for primary microglia. As shown by Anja 
Henn et al., the overall response pattern of BV2 cells was parallel to that of primary 
microglia	  (Henn et al., 2009).  
 Studies of peripheral macrophages have led to the concept of different 
macrophage activation states, ranging from ‘classical’ activation (also referred to as M1-
type macrophage activation) to so-called ‘alternative’ activation (also referred to as M2-
type macrophage activation). Classically activated microglia initiate T cell response. 
Activated microglia turn on MHC class II expression, which is required for activation of 
naive T cells, and produce numerous pro-inflammatory cytokines, including cytokines 
that induce the differentiation of effector T cells. Since microglia cells are related to 
monocytes and macrophages, they can be readily activated by cell wall components of 
bacteria such as lipopolysaccharides (LPS). It is possible that injections of LPS initiate 
signaling through macrophages that are highly enriched in the peritoneal cavity; LPS may 
also diffuse into the bloodstream, where it stimulates circulating immune cells (1996). 
Toll-like receptor 4 (TLR4) is a pattern recognition receptor that binds to pathogen-
associated molecular patterns in LPS and initiates a signaling cascade through nuclear 
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factor κB (NF-κB)-dependent and NF-κB-independent pathways (Palsson-McDermott 
and O'Ne, 2004). The peripheral LPS signal permeates the CNS and activates resident 
microglia within the brain (Glezer et al., 2003). However, it remains to be determined 
whether peripherally injected low doses of LPS directly stimulate microglia or whether 
they induce microglial activation through downstream surrogate messengers that are 
produced by immune cells or brain microvascular endothelial cells. Upon activation, 
microglia can become phagocytic and secrete a multitude of noxious cytokines, 
chemokines, and oxygen radicals. Activated microglia can also perform neuroprotective 
functions (Ransohoff and Perry, 2009). Activated microglia produce anti-inflammatory 
factors and can even sheathe neurons to provide trophic support under damaging or 
regenerating conditions. Chen et al. showed that microglial activation was not detectable 
24 hours after the first LPS injection and microglial morphology was similar to that of the 
phosphate buffered saline injected animals. Twenty-four hours after the second LPS 
injection, microglia began to retract their processes and enlarge their cell bodies. 
Interestingly, numerous spiny protrusions were seen at this interval, giving them a 
“bushy” appearance, indicating transition to activation. One day after the fourth and final 
LPS treatment, microglia demonstrated asymmetrical process distributions, dense cell 
bodies and thickened proximal dendrites. With the increasing numbers of daily LPS 
injections, the microglial activation profile expanded throughout the cortical and 
subcortical gray matter. The density of the microglial cells was quantified by Iba-1 
immunostaining.  
 Previous studies from in vitro and in vivo models demonstrated that acute alcohol 
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down-regulates LPS-induced production of proinflammatory cytokines (TNF-α, IL-6, and 
IL-1β) and up-regulates anti-inflammatory cytokines, such as IL-10. (Boe et al., 2003) 
(Mandrekar et al., 1996). The released cytokines play a central role in antimicrobial 
defense; hence, the imbalance of pro- and anti-inflammatory cytokines after acute alcohol 
exposure contributes to increased susceptibility to infections (Goral and Kovacs, 2005), 
(Oak et al., 2006). Interestingly, Harris et al. had demonstrated that activation of immune 
signaling by LPS in C57Bl/6 mice also increases their prolonged alcohol consumption 
(Blednov et al., 2011). The authors report that LPS pretreatment produces long-lasting 
increase of ethanol intake in both male and female C57Bl/6 mice. C57Bl/6 male mice 
demonstrate an increase of ethanol intake even one month after LPS injection. CD14 is a 
co-receptor, along with Toll Like Receptor 4 (TLR4) for the detection of bacterial LPS. 
The authors also show that, CD14 null mutant mice do not show increased ethanol 
consumption after pretreatment with LPS. Thus, the mechanism of action of LPS to 
increase drinking appears to be mediated by TLR’s as deletion of CD14 adaptor protein 
was sufficient to prevent an increase in ethanol consumption (Blednov et al., 2011).  
 Based on the above literature we proposed to characterize the role of NF-κB 
signaling in amplifying alcohol intake in a mouse model of LPS-enhanced alcohol 
consumption. We aimed to assess the importance of NF-κB activity in the macrophage 
compartment. Since, BV2 cells are the most frequently used substitutes for primary 
microglia we decided to use BV2 cells to perform our in vitro experiments.  
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4.2 Experimental Design and Methods 
4.2.1 Reagents and cell culture  
LPS from Escherichia coli (catalogue # L2630-100mg) was obtained from Sigma. All 
other reagents and chemicals were obtained from Sigma-Aldrich (St. Louis, MO), unless 
otherwise stated. BV2 (a murine microglial cell line) cells was maintained in DMEM 
(Cellgro) medium supplemented with 10% fetal bovine serum (Atlas Biologicals, Inc.), 2 
mM Glutamax (Life Technologies) and penicillin-streptomycin (Invitrogen) at 37 °C and 
5% CO2.  
4.2.2 SYBR green based quantitative PCR (Q-PCR) 
Cells were plated at a density of 1X 106 cells/well in 6 well plates and allowed to adhere 
overnight. The cells were first stimulated with LPS (100 ng/ml) for 2 hour followed by 
treating with 100 mM ethanol in a time dependant manner. In another experiment, cells 
were stimulated with LPS (100 ng/ml) for different time points and treated with 100 mM 
ethanol for 1 hour. BV2 cells were also stimulated with LPS (100 ng/ml) and 
simultaneously treated with 100 mM ethanol for different time points. The cells were 
harvested and total mRNA was extracted using TRIzol reagent (Ambion) and RNeasy 
Mini Kit (QIAGEN Inc., Valencia, CA) using the manufacturer's recommendations. 
Reverse transcription was performed using cDNA synthesis kit (Taqman, Life 
technologies). The RT-PCR analyses was performed using i taqTM Universal SYBR® 
supermix (Bio Rad) with 1 µl of cDNA, corresponding to 1 µg of total RNA in a 20 µl 
final volume,  8 µl H2O, 10 µl SYBR Green, 0.5 µl oligonucleotide primer pairs 
(synthesized at Sigma) at 1 mM (Table 2). PCR-program: 1. 25°C for 10 min, 2. 48°C for 
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30 min, 3. 95°C for 5 min, 4. 4°C forever. All samples were amplified in triplicates. 
18S sense 5’-CGGGTGCTCTTAGCTGAGTGTCCCG-3’ 
18S antisense 5’-CTCGGGCCTGCTTTGAACAC-3’ 
TNF alpha sense 5’-TCTCATCAGTTCTATGGCCC-3’ 
TNF alpha antisense 5’-GGGAGTAGACAAGGTACAAC-3’ 
IL-6 sense 5’-TTCCATCCAGTTGCCTTCTTG-3’ 
IL-6 antisense 5’-TTGGGAGTGGTATCCTCTGTGA-3’ 
MCP-1 sense 5’-ATCCCAATGAGTAGGCTGGAGAGC-3’ 
MCP-1 antisense 5’-CAGAAGTGCTTGAGGTGGTTGTG-3’ 
Table 4.1: SYBR green primer pairs. 
4.3 Results and Discussion  
4.3.1 Analysis of the expression of genes after LPS and ethanol treatment 
Alcohol consumption has been shown to increase in mice exposed to LPS but 
cells that participate in such behavior are still unknown. We hypothesized that LPS-
induced NF-κB signaling in microglia was pivotal in potentiating the observed alcohol 
intake in the above described model. While we have not tested our hypothesis directly, 
we have begun to analyze this possibility by treating BV2 cells with LPS followed by 
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ethanol in three different ways. First, BV2 cells were stimulated with LPS (100 ng/ml) 
for a fixed time for 2 hours, the media was aspirated out and fresh media was added with 
100 mM ethanol. The cells were incubated with ethanol for different time points. The 
cells were then harvested for RNA and analyzed by Q-PCR. We then treated another set 
of BV2 cells with LPS (100 ng/ml) for different time points. The LPS was aspirated out 
and fresh media was added. The cells were then treated with 100mM ethanol for 1 hour 
only. The cells were then harvested for RNA and analyzed by Q-PCR. Finally, we 
wanted to treat BV2 cells with LPS (100 ng/ml) and 100 mM ethanol simultaneously for 
different time points. The cells were harvested for RNA and analyzed by Q-PCR. Q-PCR 
was used to analyze the expression of pro-inflammatory cytokines like IL-6, TNF-α and 
MCP-1, as these genes are known to get upregulated upon LPS stimulation. BV2 cells 
stimulated with LPS and no ethanol treatment served as a control. However, we did not 
notice any significant difference in the expression of these genes (Figure 4.1) when 
treated with LPS for 2 hours and then ethanol.  
Interestingly, we notice a dramatic decrease in the expressions of pro-
inflammatory cytokines IL-6 and TNF-α at 2 hours. There was a decrease in the 
expression of MCP-1 genes too (Figure 4.2). When BV2 cells were treated with LPS and 
ethanol simultaneously we notice a remarkable decrease in the expression of IL-6 and 
TNF-α at 4 hours post stimulation (Figure 4.3). From our current study, we can conclude 
that upon BV2 cell stimulation by LPS followed by ethanol treatment there is a decrease 
in production of IL6, TNF-α. This suggests that ethanol is inhibitory to the production of 
inflammatory cytokines, suggesting the role of ethanol in regulating neuroinflammation. 
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4.3.2 Discussion 
NF-κB has been long recognized as the master regulator of inflammation. The 
origins of many inflammatory-associated diseases, including cancer, have been liked to 
NF-κB (Grivennikov et al., 2010) and (Karin, 2009). Importantly, it has now been 
recognized that neuroinflammation is an important component in the etiology of alcohol-
induced diseases. Alcohol consumption has been shown to increase in mice exposed to 
lipopolysaccharide (LPS), a bacterial cell wall component that binds and stimulates 
signaling of the Toll-like receptor-4 (TLR-4) pathway of which NF-κB is a downstream 
effector. Notably, mice null in components of the TLR4 signaling pathway have 
decreased alcohol-drinking behavior compared to control mice (Blednov et al., 2011). 
However, it is unclear as to which cell types of the brain contribute to the 
neuroinflammation that facilitates alcohol consumption and whether NF-κB is a major 
contributing factor in the observed neuroinflammation induced drinking model. 
So, my goal was to assess the importance of NF-κB in contributing to the LPS 
drinking model. A mouse model has been proposed for enhanced alcohol consumption in 
this study. In this model, injection of LPS induces inflammation and promotes alcohol 
drinking. Since, the immortalized murine microglial cell line BV-2 has been used 
frequently as a substitute for primary microglia, in our initial studies, we stimulated the 
BV-2 cells with LPS in a time dependent manner and treated the cells with 100 mM 
ethanol for a fixed time. The cells were harvested for RNA and Q-PCR was done to 
monitor inflammatory gene expressions as readout for NF-κB activity. Interestingly, we 
have observed that ethanol is inhibitory to the production of inflammatory cytokines only 
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when cells were treated with LPS first for different time points and then treating with 
ethanol for an hour, thus suggesting the role of ethanol in suppressing 
neuroinflammation. Previously, ethanol has been shown to have inflammatory effects on 
the brain cells. However, Wang et al. has shown that ethanol at 100 mM suppressed LPS 
induced increase of nitrite levels in rat mixed glial cells (Wang et al., 1998). Ethanol 
selectively inhibited LPS-induced NF-κB activation, but not IFNγ-induced signaling (Lee 
et al., 2004). Now our current results in BV2 cells also support this view, that ethanol at a 
dose of 100 mM is inhibitory to the production of inflammatory cytokines. 
In the recent future we plan to establish an in vivo inflammatory model in mice to 
test our hypothesis that, depending on the combination and the order the BV2 cells 
receive LPS/Ethanol, they will secrete specific cytokine signatures, which will affect 
neurons in a specific way. This project is of importance because understanding the 
molecular underpinnings of inflammation-induced drinking will provide a foundation for 
future strategies to block neuroinflammation and possibly curb drinking behavior. 
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Figure 4.1: Q-PCR to analyze the expression of inflammatory genes after a fixed 2 
hours LPS treatment followed by ethanol treatment for different time points. 
BV2 cells were stimulated with LPS (100 ng/ml) for a fixed time for 2 hours, the media 
was aspirated out and fresh media was added with 100 mM ethanol. The cells were 
incubated with ethanol for different time points. The cells were then harvested for RNA 
and analyzed by Q-PCR. 
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Figure 4.2: Q-PCR to analyze the expression of inflammatory genes after LPS 
treatment for different time points followed by ethanol treatment for 1 hour. 
BV2 cells were stimulated with LPS (100 ng/ml) for different time points. The LPS was 
aspirated out and fresh media was added. The cells were then treated with 100mM 
ethanol for 1 hour only. The cells were then harvested for RNA and analyzed by Q-PCR. 
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Figure 4.3: Q-PCR to analyze the expression of inflammatory genes after treating 
with LPS and ethanol simultaneously. 
BV2 cells were stimulated with LPS (100 ng/ml) and simultaneously treated with 100 
mM ethanol for different time points. The cells were harvested for RNA and analyzed by 
Q-PCR. 
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